#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2. Conventional Mouse Models for Liver Cancer
1-1	0-2	2.	_	_	_	_
1-2	3-15	Conventional	person[1]	new[1]	_	_
1-3	16-21	Mouse	person[1]	new[1]	_	_
1-4	22-28	Models	person[1]	new[1]	_	_
1-5	29-32	for	person[1]	new[1]	_	_
1-6	33-38	Liver	person[1]|place|abstract[3]	new[1]|new|new[3]	coref|coref	4-12|4-12[19_3]
1-7	39-45	Cancer	person[1]|abstract[3]	new[1]|new[3]	_	_

#Text=A relatively large number of mouse models are presently available for the study of hepatocarcinogenesis .
2-1	46-47	A	abstract[4]	new[4]	_	_
2-2	48-58	relatively	abstract[4]	new[4]	_	_
2-3	59-64	large	abstract[4]	new[4]	_	_
2-4	65-71	number	abstract[4]	new[4]	_	_
2-5	72-74	of	abstract[4]	new[4]	_	_
2-6	75-80	mouse	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-7	81-87	models	abstract[4]|abstract[5]	new[4]|new[5]	_	_
2-8	88-91	are	_	_	_	_
2-9	92-101	presently	_	_	_	_
2-10	102-111	available	_	_	_	_
2-11	112-115	for	_	_	_	_
2-12	116-119	the	abstract[6]	new[6]	coref	15-11[79_6]
2-13	120-125	study	abstract[6]	new[6]	_	_
2-14	126-128	of	abstract[6]	new[6]	_	_
2-15	129-149	hepatocarcinogenesis	abstract[6]|abstract	new[6]|new	coref	9-1[29_0]
2-16	150-151	.	_	_	_	_

#Text=The common ones are chemically induced models , genetically engineered mouse ( GEM ) models , implantation models , and viral models .
3-1	152-155	The	abstract[8]	new[8]	coref	3-5[9_8]
3-2	156-162	common	abstract[8]	new[8]	_	_
3-3	163-167	ones	abstract[8]	new[8]	_	_
3-4	168-171	are	_	_	_	_
3-5	172-182	chemically	abstract[9]	giv[9]	appos	3-15[12_9]
3-6	183-190	induced	abstract[9]	giv[9]	_	_
3-7	191-197	models	abstract[9]	giv[9]	_	_
3-8	198-199	,	_	_	_	_
3-9	200-211	genetically	animal[10]	new[10]	coref	4-9[0_10]
3-10	212-222	engineered	animal[10]	new[10]	_	_
3-11	223-228	mouse	animal[10]	new[10]	_	_
3-12	229-230	(	_	_	_	_
3-13	231-234	GEM	substance	new	coref	32-5
3-14	235-236	)	_	_	_	_
3-15	237-243	models	abstract[12]	giv[12]	coref	4-8[17_12]
3-16	244-245	,	abstract[12]	giv[12]	_	_
3-17	246-258	implantation	abstract[12]|abstract	giv[12]|new	_	_
3-18	259-265	models	abstract[12]	giv[12]	_	_
3-19	266-267	,	abstract[12]	giv[12]	_	_
3-20	268-271	and	abstract[12]	giv[12]	_	_
3-21	272-277	viral	abstract[12]	giv[12]	_	_
3-22	278-284	models	abstract[12]	giv[12]	_	_
3-23	285-286	.	_	_	_	_

#Text=Our aim here is not to review all mouse models for liver cancer but rather to provide examples of the representative ones , mostly chemically induced or genetically engineered models ( GEMs ) that have been integrated to genomics of human HCCs (
4-1	287-290	Our	person|abstract[15]	acc|new[15]	_	_
4-2	291-294	aim	abstract[15]	new[15]	_	_
4-3	295-299	here	_	_	_	_
4-4	300-302	is	_	_	_	_
4-5	303-306	not	_	_	_	_
4-6	307-309	to	_	_	_	_
4-7	310-316	review	_	_	_	_
4-8	317-320	all	abstract[17]	giv[17]	coref	4-20[21_17]
4-9	321-326	mouse	animal|abstract[17]	giv|giv[17]	coref	13-4[58_0]
4-10	327-333	models	abstract[17]	giv[17]	_	_
4-11	334-337	for	abstract[17]	giv[17]	_	_
4-12	338-343	liver	abstract[17]|object|abstract[19]	giv[17]|giv|giv[19]	coref|coref	10-8|10-8[35_19]
4-13	344-350	cancer	abstract[17]|abstract[19]	giv[17]|giv[19]	_	_
4-14	351-354	but	_	_	_	_
4-15	355-361	rather	_	_	_	_
4-16	362-364	to	_	_	_	_
4-17	365-372	provide	_	_	_	_
4-18	373-381	examples	abstract[20]	new[20]	_	_
4-19	382-384	of	abstract[20]	new[20]	_	_
4-20	385-388	the	abstract[20]|abstract[21]	new[20]|giv[21]	coref	4-24[22_21]
4-21	389-403	representative	abstract[20]|abstract[21]	new[20]|giv[21]	_	_
4-22	404-408	ones	abstract[20]|abstract[21]	new[20]|giv[21]	_	_
4-23	409-410	,	abstract[20]	new[20]	_	_
4-24	411-417	mostly	abstract[20]|abstract[22]	new[20]|giv[22]	coref	8-1[28_22]
4-25	418-428	chemically	abstract[20]|abstract[22]	new[20]|giv[22]	_	_
4-26	429-436	induced	abstract[20]|abstract[22]	new[20]|giv[22]	_	_
4-27	437-439	or	abstract[20]|abstract[22]	new[20]|giv[22]	_	_
4-28	440-451	genetically	abstract[20]|abstract[22]	new[20]|giv[22]	_	_
4-29	452-462	engineered	abstract[20]|abstract[22]	new[20]|giv[22]	_	_
4-30	463-469	models	abstract[20]|abstract[22]	new[20]|giv[22]	_	_
4-31	470-471	(	_	_	_	_
4-32	472-476	GEMs	object	new	_	_
4-33	477-478	)	_	_	_	_
4-34	479-483	that	_	_	_	_
4-35	484-488	have	_	_	_	_
4-36	489-493	been	_	_	_	_
4-37	494-504	integrated	_	_	_	_
4-38	505-507	to	_	_	_	_
4-39	508-516	genomics	abstract[24]	new[24]	_	_
4-40	517-519	of	abstract[24]	new[24]	_	_
4-41	520-525	human	abstract[24]|object[25]	new[24]|new[25]	coref	35-42[263_25]
4-42	526-530	HCCs	abstract[24]|object[25]	new[24]|new[25]	_	_
4-43	531-532	(	_	_	_	_

#Text=Figure 1
5-1	533-539	Figure	object[26]	new[26]	_	_
5-2	540-541	1	object[26]	new[26]	_	_

#Text=) .
6-1	542-543	)	_	_	_	_
6-2	544-545	.	_	_	_	_

#Text=2.1 .
7-1	546-549	2.1	abstract	new	_	_
7-2	550-551	.	_	_	_	_

#Text=Chemically Induced Models
8-1	552-562	Chemically	person[28]	giv[28]	_	_
8-2	563-570	Induced	person[28]	giv[28]	_	_
8-3	571-577	Models	person[28]	giv[28]	_	_

#Text=Chemically induced hepatocarcinogenesis is caused by an irreversible process of structural DNA changes .
9-1	578-588	Chemically	abstract[29]	giv[29]	coref	14-22[0_29]
9-2	589-596	induced	abstract[29]	giv[29]	_	_
9-3	597-617	hepatocarcinogenesis	abstract[29]	giv[29]	_	_
9-4	618-620	is	_	_	_	_
9-5	621-627	caused	_	_	_	_
9-6	628-630	by	_	_	_	_
9-7	631-633	an	abstract[30]	new[30]	_	_
9-8	634-646	irreversible	abstract[30]	new[30]	_	_
9-9	647-654	process	abstract[30]	new[30]	_	_
9-10	655-657	of	abstract[30]	new[30]	_	_
9-11	658-668	structural	abstract[30]|abstract[32]	new[30]|new[32]	coref	16-11[86_32]
9-12	669-672	DNA	abstract[30]|abstract|abstract[32]	new[30]|new|new[32]	coref	11-4
9-13	673-680	changes	abstract[30]|abstract[32]	new[30]|new[32]	_	_
9-14	681-682	.	_	_	_	_

#Text=The most widely used chemical to induce liver cancer in mice is diethylnitrosamine ( DEN ) ( Table 1 ) .
10-1	683-686	The	substance[33]	new[33]	coref	10-13[0_33]
10-2	687-691	most	substance[33]	new[33]	_	_
10-3	692-698	widely	substance[33]	new[33]	_	_
10-4	699-703	used	substance[33]	new[33]	_	_
10-5	704-712	chemical	substance[33]	new[33]	_	_
10-6	713-715	to	_	_	_	_
10-7	716-722	induce	_	_	_	_
10-8	723-728	liver	object|abstract[35]	giv|giv[35]	coref	34-4[0_35]
10-9	729-735	cancer	abstract[35]	giv[35]	_	_
10-10	736-738	in	_	_	_	_
10-11	739-743	mice	animal	new	coref	11-11[42_0]
10-12	744-746	is	_	_	_	_
10-13	747-765	diethylnitrosamine	substance	giv	coref	25-9
10-14	766-767	(	_	_	_	_
10-15	768-771	DEN	abstract	new	coref	11-1
10-16	772-773	)	_	_	_	_
10-17	774-775	(	_	_	_	_
10-18	776-781	Table	_	_	_	_
10-19	782-783	1	_	_	_	_
10-20	784-785	)	_	_	_	_
10-21	786-787	.	_	_	_	_

#Text=DEN is a DNA alkylating agent and when injected into juvenile mice , it forms mutagenic DNA adducts , which are generated rapidly in centrilobular hepatocytes .
11-1	788-791	DEN	substance	giv	ana	11-14
11-2	792-794	is	_	_	_	_
11-3	795-796	a	person[41]	new[41]	_	_
11-4	797-800	DNA	substance|person[41]	giv|new[41]	coref	11-17
11-5	801-811	alkylating	person[41]	new[41]	_	_
11-6	812-817	agent	person[41]	new[41]	_	_
11-7	818-821	and	_	_	_	_
11-8	822-826	when	_	_	_	_
11-9	827-835	injected	_	_	_	_
11-10	836-840	into	_	_	_	_
11-11	841-849	juvenile	animal[42]	giv[42]	coref	12-23[53_42]
11-12	850-854	mice	animal[42]	giv[42]	_	_
11-13	855-856	,	_	_	_	_
11-14	857-859	it	substance	giv	coref	12-1
11-15	860-865	forms	_	_	_	_
11-16	866-875	mutagenic	abstract[45]	new[45]	_	_
11-17	876-879	DNA	substance|abstract[45]	giv|new[45]	coref	14-26
11-18	880-887	adducts	abstract[45]	new[45]	_	_
11-19	888-889	,	_	_	_	_
11-20	890-895	which	_	_	_	_
11-21	896-899	are	_	_	_	_
11-22	900-909	generated	_	_	_	_
11-23	910-917	rapidly	_	_	_	_
11-24	918-920	in	_	_	_	_
11-25	921-934	centrilobular	object[46]	new[46]	coref	12-6[0_46]
11-26	935-946	hepatocytes	object[46]	new[46]	_	_
11-27	947-948	.	_	_	_	_

#Text=DEN is metabolic activated in hepatocytes by enzymes of the cytochrome P450 family and acts as a complete carcinogen if injected into young mice younger than two weeks old with actively proliferating hepatocytes resulting in dysplastic nodules , which progress to carcinoma .
12-1	949-952	DEN	substance	giv	coref	14-15
12-2	953-955	is	_	_	_	_
12-3	956-965	metabolic	person	new	_	_
12-4	966-975	activated	_	_	_	_
12-5	976-978	in	_	_	_	_
12-6	979-990	hepatocytes	object	giv	coref	12-33
12-7	991-993	by	_	_	_	_
12-8	994-1001	enzymes	abstract[50]	new[50]	_	_
12-9	1002-1004	of	abstract[50]	new[50]	_	_
12-10	1005-1008	the	abstract[50]|person[51]	new[50]|new[51]	_	_
12-11	1009-1019	cytochrome	abstract[50]|person[51]	new[50]|new[51]	_	_
12-12	1020-1024	P450	abstract[50]|person[51]	new[50]|new[51]	_	_
12-13	1025-1031	family	abstract[50]|person[51]	new[50]|new[51]	_	_
12-14	1032-1035	and	abstract[50]	new[50]	_	_
12-15	1036-1040	acts	abstract[50]|abstract	new[50]|new	_	_
12-16	1041-1043	as	abstract[50]	new[50]	_	_
12-17	1044-1045	a	abstract[50]	new[50]	_	_
12-18	1046-1054	complete	abstract[50]	new[50]	_	_
12-19	1055-1065	carcinogen	abstract[50]	new[50]	_	_
12-20	1066-1068	if	_	_	_	_
12-21	1069-1077	injected	_	_	_	_
12-22	1078-1082	into	_	_	_	_
12-23	1083-1088	young	animal[53]	giv[53]	coref	25-40[176_53]
12-24	1089-1093	mice	animal[53]	giv[53]	_	_
12-25	1094-1101	younger	animal[53]	giv[53]	_	_
12-26	1102-1106	than	_	_	_	_
12-27	1107-1110	two	time[54]	new[54]	_	_
12-28	1111-1116	weeks	time[54]	new[54]	_	_
12-29	1117-1120	old	_	_	_	_
12-30	1121-1125	with	_	_	_	_
12-31	1126-1134	actively	_	_	_	_
12-32	1135-1148	proliferating	_	_	_	_
12-33	1149-1160	hepatocytes	object	giv	_	_
12-34	1161-1170	resulting	_	_	_	_
12-35	1171-1173	in	_	_	_	_
12-36	1174-1184	dysplastic	object[56]	new[56]	_	_
12-37	1185-1192	nodules	object[56]	new[56]	_	_
12-38	1193-1194	,	_	_	_	_
12-39	1195-1200	which	_	_	_	_
12-40	1201-1209	progress	_	_	_	_
12-41	1210-1212	to	_	_	_	_
12-42	1213-1222	carcinoma	abstract	new	_	_
12-43	1223-1224	.	_	_	_	_

#Text=If given to an older mouse , additional stimulation is required for instance , phenobarbital ( PB ) , carbon tetrachloride , or high-fat diet feeding .
13-1	1225-1227	If	_	_	_	_
13-2	1228-1233	given	_	_	_	_
13-3	1234-1236	to	_	_	_	_
13-4	1237-1239	an	animal[58]	giv[58]	coref	19-15[0_58]
13-5	1240-1245	older	animal[58]	giv[58]	_	_
13-6	1246-1251	mouse	animal[58]	giv[58]	_	_
13-7	1252-1253	,	_	_	_	_
13-8	1254-1264	additional	abstract[59]	new[59]	_	_
13-9	1265-1276	stimulation	abstract[59]	new[59]	_	_
13-10	1277-1279	is	_	_	_	_
13-11	1280-1288	required	_	_	_	_
13-12	1289-1292	for	_	_	_	_
13-13	1293-1301	instance	_	_	_	_
13-14	1302-1303	,	_	_	_	_
13-15	1304-1317	phenobarbital	substance	new	_	_
13-16	1318-1319	(	_	_	_	_
13-17	1320-1322	PB	person	new	_	_
13-18	1323-1324	)	_	_	_	_
13-19	1325-1326	,	_	_	_	_
13-20	1327-1333	carbon	substance|substance[63]	new|new[63]	_	_
13-21	1334-1347	tetrachloride	substance[63]	new[63]	_	_
13-22	1348-1349	,	_	_	_	_
13-23	1350-1352	or	_	_	_	_
13-24	1353-1361	high-fat	event[64]	new[64]	coref	25-31[0_64]
13-25	1362-1366	diet	event[64]	new[64]	_	_
13-26	1367-1374	feeding	_	_	_	_
13-27	1375-1376	.	_	_	_	_

#Text=In addition , oxidative stress induced by reactive oxygen species ( ROS ) during DEN metabolization is known to contribute to hepatocarcinogenesis as they cause DNA , protein , and lipid damage .
14-1	1377-1379	In	_	_	_	_
14-2	1380-1388	addition	_	_	_	_
14-3	1389-1390	,	_	_	_	_
14-4	1391-1400	oxidative	abstract[65]	new[65]	_	_
14-5	1401-1407	stress	abstract[65]	new[65]	_	_
14-6	1408-1415	induced	_	_	_	_
14-7	1416-1418	by	_	_	_	_
14-8	1419-1427	reactive	abstract[67]	new[67]	_	_
14-9	1428-1434	oxygen	substance|abstract[67]	new|new[67]	_	_
14-10	1435-1442	species	abstract[67]	new[67]	_	_
14-11	1443-1444	(	_	_	_	_
14-12	1445-1448	ROS	substance	new	ana	14-24
14-13	1449-1450	)	_	_	_	_
14-14	1451-1457	during	_	_	_	_
14-15	1458-1461	DEN	substance|substance[70]	giv|new[70]	_	_
14-16	1462-1476	metabolization	substance[70]	new[70]	_	_
14-17	1477-1479	is	_	_	_	_
14-18	1480-1485	known	_	_	_	_
14-19	1486-1488	to	_	_	_	_
14-20	1489-1499	contribute	_	_	_	_
14-21	1500-1502	to	_	_	_	_
14-22	1503-1523	hepatocarcinogenesis	abstract	giv	coref	17-16
14-23	1524-1526	as	_	_	_	_
14-24	1527-1531	they	substance	giv	_	_
14-25	1532-1537	cause	_	_	_	_
14-26	1538-1541	DNA	substance	giv	coref	16-14
14-27	1542-1543	,	_	_	_	_
14-28	1544-1551	protein	substance	new	_	_
14-29	1552-1553	,	_	_	_	_
14-30	1554-1557	and	_	_	_	_
14-31	1558-1563	lipid	event|abstract[76]	new|new[76]	_	_
14-32	1564-1570	damage	abstract[76]	new[76]	_	_
14-33	1571-1572	.	_	_	_	_

#Text=The mutational landscape of a DEN-induced tumor was described in a recent study using the whole exome sequencing technique .
15-1	1573-1576	The	abstract[77]	new[77]	_	_
15-2	1577-1587	mutational	abstract[77]	new[77]	_	_
15-3	1588-1597	landscape	abstract[77]	new[77]	_	_
15-4	1598-1600	of	abstract[77]	new[77]	_	_
15-5	1601-1602	a	abstract[77]|abstract[78]	new[77]|new[78]	coref	33-22[0_78]
15-6	1603-1614	DEN-induced	abstract[77]|abstract[78]	new[77]|new[78]	_	_
15-7	1615-1620	tumor	abstract[77]|abstract[78]	new[77]|new[78]	_	_
15-8	1621-1624	was	_	_	_	_
15-9	1625-1634	described	_	_	_	_
15-10	1635-1637	in	_	_	_	_
15-11	1638-1639	a	abstract[79]	giv[79]	_	_
15-12	1640-1646	recent	abstract[79]	giv[79]	_	_
15-13	1647-1652	study	abstract[79]	giv[79]	_	_
15-14	1653-1658	using	_	_	_	_
15-15	1659-1662	the	abstract[82]	new[82]	_	_
15-16	1663-1668	whole	abstract[82]	new[82]	_	_
15-17	1669-1674	exome	abstract|abstract[82]	new|new[82]	_	_
15-18	1675-1685	sequencing	abstract|abstract[82]	new|new[82]	_	_
15-19	1686-1695	technique	abstract[82]	new[82]	_	_
15-20	1696-1697	.	_	_	_	_

#Text=A high burden of somatic mutation was observed and almost all of the DNA changes in the DEN-induced tumors were single-base substitutions . Four recurrently mutated genes that are putative oncogenic drivers of DEN-induced tumors were Hras , Braf , Egfr , and Apc .
16-1	1698-1699	A	abstract[83]	new[83]	_	_
16-2	1700-1704	high	abstract[83]	new[83]	_	_
16-3	1705-1711	burden	abstract[83]	new[83]	_	_
16-4	1712-1714	of	abstract[83]	new[83]	_	_
16-5	1715-1722	somatic	abstract[83]|abstract[84]	new[83]|new[84]	coref	21-2[129_84]
16-6	1723-1731	mutation	abstract[83]|abstract[84]	new[83]|new[84]	_	_
16-7	1732-1735	was	_	_	_	_
16-8	1736-1744	observed	_	_	_	_
16-9	1745-1748	and	_	_	_	_
16-10	1749-1755	almost	_	_	_	_
16-11	1756-1759	all	abstract[86]	giv[86]	coref	32-18[227_86]
16-12	1760-1762	of	abstract[86]	giv[86]	_	_
16-13	1763-1766	the	abstract[86]	giv[86]	_	_
16-14	1767-1770	DNA	substance|abstract[86]	giv|giv[86]	_	_
16-15	1771-1778	changes	abstract[86]	giv[86]	_	_
16-16	1779-1781	in	abstract[86]	giv[86]	_	_
16-17	1782-1785	the	abstract[86]|abstract[88]	giv[86]|new[88]	coref	16-34[93_88]
16-18	1786-1797	DEN-induced	abstract[86]|object|abstract[88]	giv[86]|new|new[88]	coref	16-34
16-19	1798-1804	tumors	abstract[86]|abstract[88]	giv[86]|new[88]	_	_
16-20	1805-1809	were	_	_	_	_
16-21	1810-1821	single-base	abstract[89]	new[89]	_	_
16-22	1822-1835	substitutions	abstract[89]	new[89]	_	_
16-23	1836-1837	.	_	_	_	_
16-24	1838-1842	Four	abstract[90]	new[90]	coref	20-8[124_90]
16-25	1843-1854	recurrently	abstract[90]	new[90]	_	_
16-26	1855-1862	mutated	abstract[90]	new[90]	_	_
16-27	1863-1868	genes	abstract[90]	new[90]	_	_
16-28	1869-1873	that	_	_	_	_
16-29	1874-1877	are	_	_	_	_
16-30	1878-1886	putative	_	_	_	_
16-31	1887-1896	oncogenic	person[91]	new[91]	coref	18-25[110_91]
16-32	1897-1904	drivers	person[91]	new[91]	_	_
16-33	1905-1907	of	person[91]	new[91]	_	_
16-34	1908-1919	DEN-induced	person[91]|object|abstract[93]	new[91]|giv|giv[93]	coref|coref	18-12|20-19[127_93]
16-35	1920-1926	tumors	person[91]|abstract[93]	new[91]|giv[93]	_	_
16-36	1927-1931	were	_	_	_	_
16-37	1932-1936	Hras	abstract	new	coref	17-4
16-38	1937-1938	,	_	_	_	_
16-39	1939-1943	Braf	abstract	new	coref	18-3
16-40	1944-1945	,	_	_	_	_
16-41	1946-1950	Egfr	abstract	new	coref	18-6
16-42	1951-1952	,	_	_	_	_
16-43	1953-1956	and	_	_	_	_
16-44	1957-1960	Apc	abstract	new	coref	22-6
16-45	1961-1962	.	_	_	_	_

#Text=The incidence of Hras was the highest reaching approximately 80 % suggesting selective advantage during hepatocarcinogenesis .
17-1	1963-1966	The	abstract[98]	new[98]	_	_
17-2	1967-1976	incidence	abstract[98]	new[98]	_	_
17-3	1977-1979	of	abstract[98]	new[98]	_	_
17-4	1980-1984	Hras	abstract[98]|substance	new[98]|giv	coref	18-1
17-5	1985-1988	was	_	_	_	_
17-6	1989-1992	the	_	_	_	_
17-7	1993-2000	highest	_	_	_	_
17-8	2001-2009	reaching	_	_	_	_
17-9	2010-2023	approximately	quantity[100]	new[100]	_	_
17-10	2024-2026	80	quantity[100]	new[100]	_	_
17-11	2027-2028	%	quantity[100]	new[100]	_	_
17-12	2029-2039	suggesting	_	_	_	_
17-13	2040-2049	selective	abstract[101]	new[101]	_	_
17-14	2050-2059	advantage	abstract[101]	new[101]	_	_
17-15	2060-2066	during	_	_	_	_
17-16	2067-2087	hepatocarcinogenesis	abstract	giv	coref	32-13[224_0]
17-17	2088-2089	.	_	_	_	_

#Text=Hras , Braf , and Egfr mutations were present in every DEN-induced HCC with mutual exclusivity and may replace each other in terms of oncogenic drivers .
18-1	2090-2094	Hras	substance	giv	_	_
18-2	2095-2096	,	_	_	_	_
18-3	2097-2101	Braf	abstract	giv	_	_
18-4	2102-2103	,	_	_	_	_
18-5	2104-2107	and	_	_	_	_
18-6	2108-2112	Egfr	abstract|abstract[106]	giv|new[106]	coref	34-26[249_106]
18-7	2113-2122	mutations	abstract[106]	new[106]	_	_
18-8	2123-2127	were	_	_	_	_
18-9	2128-2135	present	_	_	_	_
18-10	2136-2138	in	_	_	_	_
18-11	2139-2144	every	abstract[108]	new[108]	coref	19-21[120_108]
18-12	2145-2156	DEN-induced	abstract|abstract[108]	giv|new[108]	coref	19-14
18-13	2157-2160	HCC	abstract[108]	new[108]	_	_
18-14	2161-2165	with	_	_	_	_
18-15	2166-2172	mutual	abstract[109]	new[109]	_	_
18-16	2173-2184	exclusivity	abstract[109]	new[109]	_	_
18-17	2185-2188	and	_	_	_	_
18-18	2189-2192	may	_	_	_	_
18-19	2193-2200	replace	_	_	_	_
18-20	2201-2205	each	_	_	_	_
18-21	2206-2211	other	_	_	_	_
18-22	2212-2214	in	_	_	_	_
18-23	2215-2220	terms	_	_	_	_
18-24	2221-2223	of	_	_	_	_
18-25	2224-2233	oncogenic	person[110]	giv[110]	_	_
18-26	2234-2241	drivers	person[110]	giv[110]	_	_
18-27	2242-2243	.	_	_	_	_

#Text=Activation of the Ras/Raf/MEK/ERK signal transduction pathway was the hallmark feature in the DEN-induced mouse model which is rare in human HCC .
19-1	2244-2254	Activation	abstract[111]	new[111]	coref	19-9[116_111]
19-2	2255-2257	of	abstract[111]	new[111]	_	_
19-3	2258-2261	the	abstract[111]|place[115]	new[111]|new[115]	coref	22-18[145_115]
19-4	2262-2277	Ras/Raf/MEK/ERK	abstract[111]|abstract|place[115]	new[111]|new|new[115]	_	_
19-5	2278-2284	signal	abstract[111]|abstract|place[115]	new[111]|new|new[115]	_	_
19-6	2285-2297	transduction	abstract[111]|abstract|place[115]	new[111]|new|new[115]	_	_
19-7	2298-2305	pathway	abstract[111]|place[115]	new[111]|new[115]	_	_
19-8	2306-2309	was	_	_	_	_
19-9	2310-2313	the	abstract[116]	giv[116]	_	_
19-10	2314-2322	hallmark	abstract[116]	giv[116]	_	_
19-11	2323-2330	feature	abstract[116]	giv[116]	_	_
19-12	2331-2333	in	abstract[116]	giv[116]	_	_
19-13	2334-2337	the	abstract[116]|abstract[119]	giv[116]|new[119]	coref	21-8[131_119]
19-14	2338-2349	DEN-induced	abstract[116]|abstract|abstract[119]	giv[116]|giv|new[119]	coref	20-19
19-15	2350-2355	mouse	abstract[116]|animal|abstract[119]	giv[116]|giv|new[119]	coref	32-1[220_0]
19-16	2356-2361	model	abstract[116]|abstract[119]	giv[116]|new[119]	_	_
19-17	2362-2367	which	_	_	_	_
19-18	2368-2370	is	_	_	_	_
19-19	2371-2375	rare	_	_	_	_
19-20	2376-2378	in	_	_	_	_
19-21	2379-2384	human	abstract[120]	giv[120]	coref	24-10[155_120]
19-22	2385-2388	HCC	abstract[120]	giv[120]	_	_
19-23	2389-2390	.	_	_	_	_

#Text=Of note , TP53 and CTNNB1 , the most frequently altered genes in human were never found in DEN-induced tumors .
20-1	2391-2393	Of	_	_	_	_
20-2	2394-2398	note	abstract	new	_	_
20-3	2399-2400	,	_	_	_	_
20-4	2401-2405	TP53	abstract	new	coref	28-9
20-5	2406-2409	and	_	_	_	_
20-6	2410-2416	CTNNB1	abstract	new	coref	21-2
20-7	2417-2418	,	_	_	_	_
20-8	2419-2422	the	abstract[124]	giv[124]	coref	27-28[200_124]
20-9	2423-2427	most	abstract[124]	giv[124]	_	_
20-10	2428-2438	frequently	abstract[124]	giv[124]	_	_
20-11	2439-2446	altered	abstract[124]	giv[124]	_	_
20-12	2447-2452	genes	abstract[124]	giv[124]	_	_
20-13	2453-2455	in	abstract[124]	giv[124]	_	_
20-14	2456-2461	human	abstract[124]|person	giv[124]|new	_	_
20-15	2462-2466	were	_	_	_	_
20-16	2467-2472	never	_	_	_	_
20-17	2473-2478	found	_	_	_	_
20-18	2479-2481	in	_	_	_	_
20-19	2482-2493	DEN-induced	object|abstract[127]	giv|giv[127]	coref|coref	21-8|28-19[208_127]
20-20	2494-2500	tumors	abstract[127]	giv[127]	_	_
20-21	2501-2502	.	_	_	_	_

#Text=Although ctnnb1 mutation is not observed in DEN-induced model , its mutation is known to be observed in a two-stage model , the DEN-initiated and PB-promoted protocol .
21-1	2503-2511	Although	_	_	_	_
21-2	2512-2518	ctnnb1	abstract|abstract[129]	giv|giv[129]	coref	21-11[133_129]
21-3	2519-2527	mutation	abstract[129]	giv[129]	_	_
21-4	2528-2530	is	_	_	_	_
21-5	2531-2534	not	_	_	_	_
21-6	2535-2543	observed	_	_	_	_
21-7	2544-2546	in	_	_	_	_
21-8	2547-2558	DEN-induced	abstract|abstract[131]	giv|giv[131]	ana	21-11[0_131]
21-9	2559-2564	model	abstract[131]	giv[131]	_	_
21-10	2565-2566	,	_	_	_	_
21-11	2567-2570	its	abstract|abstract[133]	giv|giv[133]	coref|coref	21-19[134_0]|22-9[0_133]
21-12	2571-2579	mutation	abstract[133]	giv[133]	_	_
21-13	2580-2582	is	_	_	_	_
21-14	2583-2588	known	_	_	_	_
21-15	2589-2591	to	_	_	_	_
21-16	2592-2594	be	_	_	_	_
21-17	2595-2603	observed	_	_	_	_
21-18	2604-2606	in	_	_	_	_
21-19	2607-2608	a	abstract[134]	giv[134]	coref	23-1[147_134]
21-20	2609-2618	two-stage	abstract[134]	giv[134]	_	_
21-21	2619-2624	model	abstract[134]	giv[134]	_	_
21-22	2625-2626	,	_	_	_	_
21-23	2627-2630	the	abstract[137]	new[137]	_	_
21-24	2631-2644	DEN-initiated	abstract|abstract[137]	new|new[137]	_	_
21-25	2645-2648	and	abstract[137]	new[137]	_	_
21-26	2649-2660	PB-promoted	abstract|abstract[137]	new|new[137]	_	_
21-27	2661-2669	protocol	abstract[137]	new[137]	_	_
21-28	2670-2671	.	_	_	_	_

#Text=In addition , loss of Apc function , mutation and aberrant nuclear expression of β-catenin may disrupt the canonical Wnt/β-catenin pathway .
22-1	2672-2674	In	_	_	_	_
22-2	2675-2683	addition	_	_	_	_
22-3	2684-2685	,	_	_	_	_
22-4	2686-2690	loss	event[138]	new[138]	_	_
22-5	2691-2693	of	event[138]	new[138]	_	_
22-6	2694-2697	Apc	event[138]|organization|abstract[140]	new[138]|giv|new[140]	_	_
22-7	2698-2706	function	event[138]|abstract[140]	new[138]|new[140]	_	_
22-8	2707-2708	,	event[138]	new[138]	_	_
22-9	2709-2717	mutation	event[138]|abstract	new[138]|giv	coref	27-6
22-10	2718-2721	and	event[138]	new[138]	_	_
22-11	2722-2730	aberrant	event[138]|abstract[142]	new[138]|new[142]	_	_
22-12	2731-2738	nuclear	event[138]|abstract[142]	new[138]|new[142]	_	_
22-13	2739-2749	expression	event[138]|abstract[142]	new[138]|new[142]	_	_
22-14	2750-2752	of	event[138]|abstract[142]	new[138]|new[142]	_	_
22-15	2753-2762	β-catenin	event[138]|abstract[142]|substance	new[138]|new[142]|new	_	_
22-16	2763-2766	may	_	_	_	_
22-17	2767-2774	disrupt	_	_	_	_
22-18	2775-2778	the	place[145]	giv[145]	coref	27-5[0_145]
22-19	2779-2788	canonical	place[145]	giv[145]	_	_
22-20	2789-2802	Wnt/β-catenin	abstract|place[145]	new|giv[145]	_	_
22-21	2803-2810	pathway	place[145]	giv[145]	_	_
22-22	2811-2812	.	_	_	_	_

#Text=The Stelic Animal Model ( STAM ) demonstrates non-alcoholic steatohepatitis ( NASH ) progression resembling the disease in humans .
23-1	2813-2816	The	abstract[147]	giv[147]	appos	23-6[0_147]
23-2	2817-2823	Stelic	person|abstract[147]	new|giv[147]	_	_
23-3	2824-2830	Animal	abstract[147]	giv[147]	_	_
23-4	2831-2836	Model	abstract[147]	giv[147]	_	_
23-5	2837-2838	(	_	_	_	_
23-6	2839-2843	STAM	abstract	giv	coref	25-1[162_0]
23-7	2844-2845	)	_	_	_	_
23-8	2846-2858	demonstrates	_	_	_	_
23-9	2859-2872	non-alcoholic	abstract[149]	new[149]	appos	23-12[0_149]
23-10	2873-2888	steatohepatitis	abstract[149]	new[149]	_	_
23-11	2889-2890	(	_	_	_	_
23-12	2891-2895	NASH	abstract	giv	coref	24-2
23-13	2896-2897	)	_	_	_	_
23-14	2898-2909	progression	abstract	new	coref	32-25
23-15	2910-2920	resembling	_	_	_	_
23-16	2921-2924	the	abstract[152]	new[152]	coref	32-27[0_152]
23-17	2925-2932	disease	abstract[152]	new[152]	_	_
23-18	2933-2935	in	_	_	_	_
23-19	2936-2942	humans	person	new	coref	27-12[192_0]
23-20	2943-2944	.	_	_	_	_

#Text=Since NASH is evolving as a major cause of non-viral HCC and may account for a large proportion of HCC in developed countries in recent years , HCC arising from NASH is important .
24-1	2945-2950	Since	_	_	_	_
24-2	2951-2955	NASH	substance	giv	coref	24-31
24-3	2956-2958	is	_	_	_	_
24-4	2959-2967	evolving	_	_	_	_
24-5	2968-2970	as	_	_	_	_
24-6	2971-2972	a	_	_	_	_
24-7	2973-2978	major	_	_	_	_
24-8	2979-2984	cause	_	_	_	_
24-9	2985-2987	of	_	_	_	_
24-10	2988-2997	non-viral	abstract[155]	giv[155]	coref	24-20[0_155]
24-11	2998-3001	HCC	abstract[155]	giv[155]	_	_
24-12	3002-3005	and	_	_	_	_
24-13	3006-3009	may	_	_	_	_
24-14	3010-3017	account	_	_	_	_
24-15	3018-3021	for	_	_	_	_
24-16	3022-3023	a	quantity[156]	new[156]	_	_
24-17	3024-3029	large	quantity[156]	new[156]	_	_
24-18	3030-3040	proportion	quantity[156]	new[156]	_	_
24-19	3041-3043	of	quantity[156]	new[156]	_	_
24-20	3044-3047	HCC	quantity[156]|abstract	new[156]|giv	coref	24-28
24-21	3048-3050	in	_	_	_	_
24-22	3051-3060	developed	place[158]	new[158]	_	_
24-23	3061-3070	countries	place[158]	new[158]	_	_
24-24	3071-3073	in	place[158]	new[158]	_	_
24-25	3074-3080	recent	place[158]|time[159]	new[158]|new[159]	_	_
24-26	3081-3086	years	place[158]|time[159]	new[158]|new[159]	_	_
24-27	3087-3088	,	_	_	_	_
24-28	3089-3092	HCC	abstract	giv	coref	26-21
24-29	3093-3100	arising	_	_	_	_
24-30	3101-3105	from	_	_	_	_
24-31	3106-3110	NASH	abstract	giv	coref	26-4
24-32	3111-3113	is	_	_	_	_
24-33	3114-3123	important	_	_	_	_
24-34	3124-3125	.	_	_	_	_

#Text=The STAM model is created by combination of chemical ( a single subcutaneous injection of 200 μg of streptozotocin at two days after birth ) and dietary intervention ( high-fat diet ad libitum four weeks after injection ) in C57BL/6 mice .
25-1	3126-3129	The	abstract[162]	giv[162]	coref	26-1[0_162]
25-2	3130-3134	STAM	abstract[162]	giv[162]	_	_
25-3	3135-3140	model	abstract[162]	giv[162]	_	_
25-4	3141-3143	is	_	_	_	_
25-5	3144-3151	created	_	_	_	_
25-6	3152-3154	by	_	_	_	_
25-7	3155-3166	combination	abstract[163]	new[163]	_	_
25-8	3167-3169	of	abstract[163]	new[163]	_	_
25-9	3170-3178	chemical	abstract[163]|substance	new[163]|giv	_	_
25-10	3179-3180	(	_	_	_	_
25-11	3181-3182	a	event[165]	new[165]	coref	25-37[0_165]
25-12	3183-3189	single	event[165]	new[165]	_	_
25-13	3190-3202	subcutaneous	event[165]	new[165]	_	_
25-14	3203-3212	injection	event[165]	new[165]	_	_
25-15	3213-3215	of	event[165]	new[165]	_	_
25-16	3216-3219	200	event[165]|quantity[166]	new[165]|new[166]	_	_
25-17	3220-3222	μg	event[165]|quantity[166]	new[165]|new[166]	_	_
25-18	3223-3225	of	event[165]|quantity[166]	new[165]|new[166]	_	_
25-19	3226-3240	streptozotocin	event[165]|quantity[166]|substance	new[165]|new[166]|new	_	_
25-20	3241-3243	at	event[165]	new[165]	_	_
25-21	3244-3247	two	event[165]|time[168]	new[165]|new[168]	_	_
25-22	3248-3252	days	event[165]|time[168]	new[165]|new[168]	_	_
25-23	3253-3258	after	event[165]|time[168]	new[165]|new[168]	_	_
25-24	3259-3264	birth	event[165]|time[168]|event	new[165]|new[168]|new	_	_
25-25	3265-3266	)	_	_	_	_
25-26	3267-3270	and	_	_	_	_
25-27	3271-3278	dietary	abstract|event[171]	new|new[171]	_	_
25-28	3279-3291	intervention	event[171]	new[171]	_	_
25-29	3292-3293	(	_	_	_	_
25-30	3294-3302	high-fat	_	_	_	_
25-31	3303-3307	diet	event	giv	_	_
25-32	3308-3310	ad	_	_	_	_
25-33	3311-3318	libitum	_	_	_	_
25-34	3319-3323	four	time[173]	new[173]	_	_
25-35	3324-3329	weeks	time[173]	new[173]	_	_
25-36	3330-3335	after	time[173]	new[173]	_	_
25-37	3336-3345	injection	time[173]|event	new[173]|giv	_	_
25-38	3346-3347	)	_	_	_	_
25-39	3348-3350	in	_	_	_	_
25-40	3351-3358	C57BL/6	animal|animal[176]	new|giv[176]	coref	26-1[178_176]
25-41	3359-3363	mice	animal[176]	giv[176]	_	_
25-42	3364-3365	.	_	_	_	_

#Text=STAM mice manifest NASH at eight weeks , which progresses to fibrosis at 12 weeks , and eventually develops into HCC at a rate of nearly 100 % in males .
26-1	3366-3370	STAM	animal|animal[178]	giv|giv[178]	coref	27-1[187_0]
26-2	3371-3375	mice	animal[178]	giv[178]	_	_
26-3	3376-3384	manifest	_	_	_	_
26-4	3385-3389	NASH	object	giv	coref	29-26
26-5	3390-3392	at	_	_	_	_
26-6	3393-3398	eight	time[180]	new[180]	_	_
26-7	3399-3404	weeks	time[180]	new[180]	_	_
26-8	3405-3406	,	_	_	_	_
26-9	3407-3412	which	_	_	_	_
26-10	3413-3423	progresses	_	_	_	_
26-11	3424-3426	to	_	_	_	_
26-12	3427-3435	fibrosis	object	new	_	_
26-13	3436-3438	at	_	_	_	_
26-14	3439-3441	12	time[182]	new[182]	_	_
26-15	3442-3447	weeks	time[182]	new[182]	_	_
26-16	3448-3449	,	_	_	_	_
26-17	3450-3453	and	_	_	_	_
26-18	3454-3464	eventually	_	_	_	_
26-19	3465-3473	develops	_	_	_	_
26-20	3474-3478	into	_	_	_	_
26-21	3479-3482	HCC	object	giv	coref	34-15
26-22	3483-3485	at	_	_	_	_
26-23	3486-3487	a	abstract[184]	new[184]	_	_
26-24	3488-3492	rate	abstract[184]	new[184]	_	_
26-25	3493-3495	of	abstract[184]	new[184]	_	_
26-26	3496-3502	nearly	abstract[184]|quantity[185]	new[184]|new[185]	_	_
26-27	3503-3506	100	abstract[184]|quantity[185]	new[184]|new[185]	_	_
26-28	3507-3508	%	abstract[184]|quantity[185]	new[184]|new[185]	_	_
26-29	3509-3511	in	abstract[184]|quantity[185]	new[184]|new[185]	_	_
26-30	3512-3517	males	abstract[184]|quantity[185]|person	new[184]|new[185]|new	_	_
26-31	3518-3519	.	_	_	_	_

#Text=The STAM model had pathway mutation rates comparable to those in humans for most pathways with more alterations in receptor tyrosine kinase ( RTK ) signaling and chromatin-modification genes .
27-1	3520-3523	The	abstract[187]	giv[187]	ana	27-10[191_187]
27-2	3524-3528	STAM	abstract[187]	giv[187]	_	_
27-3	3529-3534	model	abstract[187]	giv[187]	_	_
27-4	3535-3538	had	_	_	_	_
27-5	3539-3546	pathway	place|abstract[190]	giv|new[190]	coref	28-13
27-6	3547-3555	mutation	abstract|abstract[190]	giv|new[190]	coref	28-6
27-7	3556-3561	rates	abstract[190]	new[190]	_	_
27-8	3562-3572	comparable	abstract[190]	new[190]	_	_
27-9	3573-3575	to	_	_	_	_
27-10	3576-3581	those	abstract[191]	giv[191]	coref	28-1[201_191]
27-11	3582-3584	in	abstract[191]	giv[191]	_	_
27-12	3585-3591	humans	abstract[191]|person[192]	giv[191]|giv[192]	_	_
27-13	3592-3595	for	abstract[191]|person[192]	giv[191]|giv[192]	_	_
27-14	3596-3600	most	abstract[191]|person[192]|place[193]	giv[191]|giv[192]|new[193]	coref	35-1[253_193]
27-15	3601-3609	pathways	abstract[191]|person[192]|place[193]	giv[191]|giv[192]|new[193]	_	_
27-16	3610-3614	with	abstract[191]|person[192]|place[193]	giv[191]|giv[192]|new[193]	_	_
27-17	3615-3619	more	abstract[191]|person[192]|place[193]|abstract[194]	giv[191]|giv[192]|new[193]|new[194]	coref	34-29[252_194]
27-18	3620-3631	alterations	abstract[191]|person[192]|place[193]|abstract[194]	giv[191]|giv[192]|new[193]|new[194]	_	_
27-19	3632-3634	in	abstract[191]|person[192]|place[193]|abstract[194]	giv[191]|giv[192]|new[193]|new[194]	_	_
27-20	3635-3643	receptor	abstract[191]|person[192]|place[193]|abstract[194]|substance|abstract[197]	giv[191]|giv[192]|new[193]|new[194]|new|new[197]	appos	27-24[0_197]
27-21	3644-3652	tyrosine	abstract[191]|person[192]|place[193]|abstract[194]|abstract|abstract[197]	giv[191]|giv[192]|new[193]|new[194]|new|new[197]	_	_
27-22	3653-3659	kinase	abstract[191]|person[192]|place[193]|abstract[194]|abstract[197]	giv[191]|giv[192]|new[193]|new[194]|new[197]	_	_
27-23	3660-3661	(	abstract[191]|person[192]|place[193]|abstract[194]	giv[191]|giv[192]|new[193]|new[194]	_	_
27-24	3662-3665	RTK	abstract[191]|person[192]|place[193]|abstract[194]|abstract	giv[191]|giv[192]|new[193]|new[194]|giv	_	_
27-25	3666-3667	)	abstract[191]|person[192]|place[193]|abstract[194]	giv[191]|giv[192]|new[193]|new[194]	_	_
27-26	3668-3677	signaling	abstract[191]|person[192]|place[193]|abstract[194]|abstract	giv[191]|giv[192]|new[193]|new[194]|new	_	_
27-27	3678-3681	and	abstract[191]|person[192]|place[193]|abstract[194]	giv[191]|giv[192]|new[193]|new[194]	_	_
27-28	3682-3704	chromatin-modification	abstract[191]|person[192]|place[193]|abstract[194]|abstract[200]	giv[191]|giv[192]|new[193]|new[194]|giv[200]	_	_
27-29	3705-3710	genes	abstract[191]|person[192]|place[193]|abstract[194]|abstract[200]	giv[191]|giv[192]|new[193]|new[194]|giv[200]	_	_
27-30	3711-3712	.	_	_	_	_

#Text=This model also showed low mutation rate of TP53 but the cell-cycle pathway alteration rate was similar to human tumors .
28-1	3713-3717	This	abstract[201]	giv[201]	coref	29-4[210_201]
28-2	3718-3723	model	abstract[201]	giv[201]	_	_
28-3	3724-3728	also	_	_	_	_
28-4	3729-3735	showed	_	_	_	_
28-5	3736-3739	low	abstract[203]	new[203]	coref	28-11[207_203]
28-6	3740-3748	mutation	abstract|abstract[203]	giv|new[203]	_	_
28-7	3749-3753	rate	abstract[203]	new[203]	_	_
28-8	3754-3756	of	abstract[203]	new[203]	_	_
28-9	3757-3761	TP53	abstract[203]|abstract	new[203]|giv	_	_
28-10	3762-3765	but	_	_	_	_
28-11	3766-3769	the	abstract[207]	giv[207]	_	_
28-12	3770-3780	cell-cycle	abstract[207]	giv[207]	_	_
28-13	3781-3788	pathway	place|abstract[207]	giv|giv[207]	coref	35-6[255_0]
28-14	3789-3799	alteration	abstract|abstract[207]	new|giv[207]	_	_
28-15	3800-3804	rate	abstract[207]	giv[207]	_	_
28-16	3805-3808	was	_	_	_	_
28-17	3809-3816	similar	_	_	_	_
28-18	3817-3819	to	_	_	_	_
28-19	3820-3825	human	abstract[208]	giv[208]	_	_
28-20	3826-3832	tumors	abstract[208]	giv[208]	_	_
28-21	3833-3834	.	_	_	_	_

#Text=The limitation of this model is that the model does not show obesity or insulin resistance , which is the common characteristics of patients with NASH .
29-1	3835-3838	The	abstract[209]	new[209]	_	_
29-2	3839-3849	limitation	abstract[209]	new[209]	_	_
29-3	3850-3852	of	abstract[209]	new[209]	_	_
29-4	3853-3857	this	abstract[209]|abstract[210]	new[209]|giv[210]	coref	29-8[211_210]
29-5	3858-3863	model	abstract[209]|abstract[210]	new[209]|giv[210]	_	_
29-6	3864-3866	is	_	_	_	_
29-7	3867-3871	that	_	_	_	_
29-8	3872-3875	the	abstract[211]	giv[211]	_	_
29-9	3876-3881	model	abstract[211]	giv[211]	_	_
29-10	3882-3886	does	_	_	_	_
29-11	3887-3890	not	_	_	_	_
29-12	3891-3895	show	_	_	_	_
29-13	3896-3903	obesity	abstract	new	_	_
29-14	3904-3906	or	_	_	_	_
29-15	3907-3914	insulin	event|abstract[214]	new|new[214]	_	_
29-16	3915-3925	resistance	abstract[214]	new[214]	_	_
29-17	3926-3927	,	_	_	_	_
29-18	3928-3933	which	_	_	_	_
29-19	3934-3936	is	_	_	_	_
29-20	3937-3940	the	abstract[215]	new[215]	_	_
29-21	3941-3947	common	abstract[215]	new[215]	_	_
29-22	3948-3963	characteristics	abstract[215]	new[215]	_	_
29-23	3964-3966	of	abstract[215]	new[215]	_	_
29-24	3967-3975	patients	abstract[215]|person[216]	new[215]|new[216]	_	_
29-25	3976-3980	with	abstract[215]|person[216]	new[215]|new[216]	_	_
29-26	3981-3985	NASH	abstract[215]|person[216]|abstract	new[215]|new[216]|giv	_	_
29-27	3986-3987	.	_	_	_	_

#Text=2.2 .
30-1	3988-3991	2.2	abstract	new	_	_
30-2	3992-3993	.	_	_	_	_

#Text=Genetically Engineered Mouse Models
31-1	3994-4005	Genetically	abstract[219]	new[219]	coref	32-7[0_219]
31-2	4006-4016	Engineered	abstract[219]	new[219]	_	_
31-3	4017-4022	Mouse	abstract[219]	new[219]	_	_
31-4	4023-4029	Models	abstract[219]	new[219]	_	_

#Text=Genetically engineered mouse ( GEM ) models recapitulate the multistep process of hepatocarcinogenesis with multiple genetic and epigenetic changes occurring along each stage of progression toward cancer formation .
32-1	4030-4041	Genetically	animal[220]	giv[220]	_	_
32-2	4042-4052	engineered	animal[220]	giv[220]	_	_
32-3	4053-4058	mouse	animal[220]	giv[220]	_	_
32-4	4059-4060	(	_	_	_	_
32-5	4061-4064	GEM	substance	giv	_	_
32-6	4065-4066	)	_	_	_	_
32-7	4067-4073	models	abstract	giv	_	_
32-8	4074-4086	recapitulate	_	_	_	_
32-9	4087-4090	the	abstract[223]	new[223]	_	_
32-10	4091-4100	multistep	abstract[223]	new[223]	_	_
32-11	4101-4108	process	abstract[223]	new[223]	_	_
32-12	4109-4111	of	abstract[223]	new[223]	_	_
32-13	4112-4132	hepatocarcinogenesis	abstract[223]|abstract[224]	new[223]|giv[224]	_	_
32-14	4133-4137	with	abstract[223]|abstract[224]	new[223]|giv[224]	_	_
32-15	4138-4146	multiple	abstract[223]|abstract[224]|abstract[225]	new[223]|giv[224]|new[225]	_	_
32-16	4147-4154	genetic	abstract[223]|abstract[224]|abstract[225]	new[223]|giv[224]|new[225]	_	_
32-17	4155-4158	and	abstract[223]|abstract[224]	new[223]|giv[224]	_	_
32-18	4159-4169	epigenetic	abstract[223]|abstract[224]|abstract|abstract[227]	new[223]|giv[224]|new|giv[227]	ana	33-1[0_227]
32-19	4170-4177	changes	abstract[223]|abstract[224]|abstract[227]	new[223]|giv[224]|giv[227]	_	_
32-20	4178-4187	occurring	_	_	_	_
32-21	4188-4193	along	_	_	_	_
32-22	4194-4198	each	event[228]	new[228]	_	_
32-23	4199-4204	stage	event[228]	new[228]	_	_
32-24	4205-4207	of	event[228]	new[228]	_	_
32-25	4208-4219	progression	event[228]|event	new[228]|giv	_	_
32-26	4220-4226	toward	event[228]	new[228]	_	_
32-27	4227-4233	cancer	event[228]|abstract|abstract[231]	new[228]|giv|new[231]	_	_
32-28	4234-4243	formation	event[228]|abstract[231]	new[228]|new[231]	_	_
32-29	4244-4245	.	_	_	_	_

#Text=They are highly useful for assessing the impacts of a driver oncogene alone or in combination with other driver oncogenes or tumor suppressors .
33-1	4246-4250	They	abstract	giv	_	_
33-2	4251-4254	are	_	_	_	_
33-3	4255-4261	highly	_	_	_	_
33-4	4262-4268	useful	_	_	_	_
33-5	4269-4272	for	_	_	_	_
33-6	4273-4282	assessing	_	_	_	_
33-7	4283-4286	the	abstract[233]	new[233]	_	_
33-8	4287-4294	impacts	abstract[233]	new[233]	_	_
33-9	4295-4297	of	abstract[233]	new[233]	_	_
33-10	4298-4299	a	abstract[233]|abstract[235]	new[233]|new[235]	_	_
33-11	4300-4306	driver	abstract[233]|person|abstract[235]	new[233]|new|new[235]	coref	33-19
33-12	4307-4315	oncogene	abstract[233]|abstract[235]	new[233]|new[235]	_	_
33-13	4316-4321	alone	abstract[233]|abstract[235]	new[233]|new[235]	_	_
33-14	4322-4324	or	_	_	_	_
33-15	4325-4327	in	_	_	_	_
33-16	4328-4339	combination	_	_	_	_
33-17	4340-4344	with	_	_	_	_
33-18	4345-4350	other	abstract[237]	new[237]	_	_
33-19	4351-4357	driver	person|abstract[237]	giv|new[237]	_	_
33-20	4358-4367	oncogenes	abstract[237]	new[237]	_	_
33-21	4368-4370	or	_	_	_	_
33-22	4371-4376	tumor	abstract|object[239]	giv|new[239]	_	_
33-23	4377-4388	suppressors	object[239]	new[239]	_	_
33-24	4389-4390	.	_	_	_	_

#Text=Recently , the Cancer Genome Atlas ( TCGA ) characterized the genomic landscape of HCC using large-scale multi-platform analysis of HCC , including evaluation of somatic mutations and copy number alterations .
34-1	4391-4399	Recently	_	_	_	_
34-2	4400-4401	,	_	_	_	_
34-3	4402-4405	the	person[242]	new[242]	_	_
34-4	4406-4412	Cancer	abstract|person[242]	giv|new[242]	_	_
34-5	4413-4419	Genome	abstract|person[242]	new|new[242]	_	_
34-6	4420-4425	Atlas	person[242]	new[242]	_	_
34-7	4426-4427	(	_	_	_	_
34-8	4428-4432	TCGA	abstract	new	_	_
34-9	4433-4434	)	_	_	_	_
34-10	4435-4448	characterized	_	_	_	_
34-11	4449-4452	the	abstract[244]	new[244]	_	_
34-12	4453-4460	genomic	abstract[244]	new[244]	_	_
34-13	4461-4470	landscape	abstract[244]	new[244]	_	_
34-14	4471-4473	of	abstract[244]	new[244]	_	_
34-15	4474-4477	HCC	abstract[244]|organization	new[244]|giv	coref	34-21
34-16	4478-4483	using	_	_	_	_
34-17	4484-4495	large-scale	abstract[246]	new[246]	_	_
34-18	4496-4510	multi-platform	abstract[246]	new[246]	_	_
34-19	4511-4519	analysis	abstract[246]	new[246]	_	_
34-20	4520-4522	of	abstract[246]	new[246]	_	_
34-21	4523-4526	HCC	abstract[246]|object	new[246]|giv	_	_
34-22	4527-4528	,	abstract[246]	new[246]	_	_
34-23	4529-4538	including	abstract[246]	new[246]	_	_
34-24	4539-4549	evaluation	abstract[246]|abstract[248]	new[246]|new[248]	_	_
34-25	4550-4552	of	abstract[246]|abstract[248]	new[246]|new[248]	_	_
34-26	4553-4560	somatic	abstract[246]|abstract[248]|abstract[249]	new[246]|new[248]|giv[249]	_	_
34-27	4561-4570	mutations	abstract[246]|abstract[248]|abstract[249]	new[246]|new[248]|giv[249]	_	_
34-28	4571-4574	and	abstract[246]|abstract[248]|abstract[249]	new[246]|new[248]|giv[249]	_	_
34-29	4575-4579	copy	abstract[246]|abstract[248]|abstract[249]|object|abstract[252]	new[246]|new[248]|giv[249]|new|giv[252]	_	_
34-30	4580-4586	number	abstract[246]|abstract[248]|abstract[249]|place|abstract[252]	new[246]|new[248]|giv[249]|new|giv[252]	_	_
34-31	4587-4598	alterations	abstract[246]|abstract[248]|abstract[249]|abstract[252]	new[246]|new[248]|giv[249]|giv[252]	_	_
34-32	4599-4600	.	_	_	_	_

#Text=Commonly altered pathways such as cell cycle pathway , RTK/RAS/PI3K , and WNT pathways were also identified and therefore , data generated from GEMs would be useful in developing novel therapies and be tested in the preclinical setting if they recapitulate human HCCs .
35-1	4601-4609	Commonly	place[253]	giv[253]	_	_
35-2	4610-4617	altered	place[253]	giv[253]	_	_
35-3	4618-4626	pathways	place[253]	giv[253]	_	_
35-4	4627-4631	such	place[253]	giv[253]	_	_
35-5	4632-4634	as	place[253]	giv[253]	_	_
35-6	4635-4639	cell	place[253]|place[255]	giv[253]|giv[255]	_	_
35-7	4640-4645	cycle	place[253]|abstract|place[255]	giv[253]|new|giv[255]	_	_
35-8	4646-4653	pathway	place[253]|place[255]	giv[253]|giv[255]	_	_
35-9	4654-4655	,	place[253]	giv[253]	_	_
35-10	4656-4668	RTK/RAS/PI3K	place[253]|abstract	giv[253]|new	_	_
35-11	4669-4670	,	place[253]	giv[253]	_	_
35-12	4671-4674	and	place[253]	giv[253]	_	_
35-13	4675-4678	WNT	place[253]|abstract	giv[253]|new	_	_
35-14	4679-4687	pathways	place[253]	giv[253]	_	_
35-15	4688-4692	were	_	_	_	_
35-16	4693-4697	also	_	_	_	_
35-17	4698-4708	identified	_	_	_	_
35-18	4709-4712	and	_	_	_	_
35-19	4713-4722	therefore	_	_	_	_
35-20	4723-4724	,	_	_	_	_
35-21	4725-4729	data	abstract	new	_	_
35-22	4730-4739	generated	_	_	_	_
35-23	4740-4744	from	_	_	_	_
35-24	4745-4749	GEMs	object	new	ana	35-40
35-25	4750-4755	would	_	_	_	_
35-26	4756-4758	be	_	_	_	_
35-27	4759-4765	useful	_	_	_	_
35-28	4766-4768	in	_	_	_	_
35-29	4769-4779	developing	_	_	_	_
35-30	4780-4785	novel	abstract[260]	new[260]	_	_
35-31	4786-4795	therapies	abstract[260]	new[260]	_	_
35-32	4796-4799	and	_	_	_	_
35-33	4800-4802	be	_	_	_	_
35-34	4803-4809	tested	_	_	_	_
35-35	4810-4812	in	_	_	_	_
35-36	4813-4816	the	abstract[261]	new[261]	_	_
35-37	4817-4828	preclinical	abstract[261]	new[261]	_	_
35-38	4829-4836	setting	abstract[261]	new[261]	_	_
35-39	4837-4839	if	_	_	_	_
35-40	4840-4844	they	object	giv	_	_
35-41	4845-4857	recapitulate	_	_	_	_
35-42	4858-4863	human	object[263]	giv[263]	_	_
35-43	4864-4868	HCCs	object[263]	giv[263]	_	_
35-44	4869-4870	.	_	_	_	_
